Table of contents :
|
|
|
Blood / haema / hema / sanguis : the fluid that circulates through the heart, arteries, capillaries, and veins, carrying nutriment and oxygen to the body cells. It consists of the plasma, a pale yellow liquid containing the microscopically visible formed elements of the blood: the erythrocytes, or red blood corpuscles; the leukocytes, or white blood corpuscles; and the platelets, or thrombocytes. Its amount in a normal adult is ~ 5 L (~ 7% of body volume or 8.5-9.0% of body mass) :

|
|
|
|
|
|
|
|
|
| 1 | a-spectrin (SPTA1) | 281 | 1q22-q23 | membrane skeleton | band 3, ankyrin | peripheral | hereditary
elliptocytosis |
| 1 | b-spectrin (SPTB) | 246 | 14q23-q24.1 | hereditary
spherocytosis |
|||
| 2.1 | ankyrin 1 (ANK1) | 206 | 8p11.2 | binds membrane protien and cytoskeleton | band 3, b-spectrin | peripheral | |
| 2.9 | a-adducin / adductin 1 (ADD1) | 81 | 4p16.3 | binds actin filaments | spectrin, b-actin | peripheral | |
| 2.9 | b-adducin / adducin 2 (ADD2) | 80 | binds actin filaments | spectrin, b-actin | peripheral | ||
| 3 | SLC4A1
/ erythrocyte membrane protein band 3 / anion exchange protein 1 (AE1)
/ CD233 |
102 | 17q12-q21 | anion transport | ankyrin, spectrin, protein 4.1 | integral | hereditary
elliptocytosis |
| 4.1 | erythrocyte membrane protein band 4.1 (EPB41) | 66 | 1p33-p34.1 | membrane skeleton | spectrin, b-actin, GPC | peripheral | hereditary
elliptocytosis |
| 4.2 | pallidin | 77 | 5q15-q21 | binds cytoskeleton to lipid bilayer | band 3, ankyrin | peripheral | |
| 4.9 | dematin / EPB49 (a, b) | 43+46 | 8p21.2-21.1 | actin-binding protein | b-actin, lipids | peripheral | |
| 4.9 | p55 / MPP1 | 53 | Xq28 | protein 4.1, GPC | peripheral | ||
| 5 | b-actin | 42 | 7pter-q22 | membrane skeleton | spectrin, protein 4.1 | peripheral | |
| 5 | tropomodulin | 41 | 9q22 | blocks growth of actin filaments | tropomyosin, b-actin | peripheral | |
| 6 | GADPH | 36 | 12q13 | band 3 | peripheral | ||
| 7 | stomatin | 32 | integral | hereditary
stomatocytosis |
|||
| 7 | tropomyosin | 28 | 1q31 | stabilization of actin filaments | b-actin | peripheral | |
| 8 | protein 8 | 23 | peripheral | ||||
| GPA | glycophorin A (GYPA) / MNS blood group | 14 | 4q31 | receptor for Plasmodium falciparum | negatively-charged phospholipids | integral | none |
| GPB | CD235b / glycophorin B | 8 | 4q31 | anchor for membrane skeleton | protein 4.1 | integral | none |
| GPC | CD235R / glycophorin C (GYPC) | 14 | 2q14-q21 | protein 4.1, p55 | integral | hereditary
elliptocytosis |
|
| GPD | glycophorin D | 11 | 2q14-q21 | integral | hereditary
elliptocytosis |
||
| GPE | glycophorin E (GYPE) | 6 | 4q31 | integral |

or
+ ? :







|
|
|
|
|
|
|
|
| alkaline phosphatase (AlkP / ALP)
|
100-300 IU/L at 37°C (varies with age (peak at birth, fall at age 5, lesser peak at age 12 and fall at age 20) and temperature) | slow hepatic AlkP (normal) | substrates for spectrophotometry :
|
hepatocytes (also in bile) | cirrhosis, obstructive jaundice, liver
metastases |
scurvy magnesium deficiency infantile hypothyroidism cachexia congental hypophosphatemia Fanconi syndrome renal failure idiopathic acidosis bone radiotherapy |
| bone AlkP (bALP) (normal) (2-15 mg/L) | osteoblasts => values related to total bone mass, higher in males | tumours, rickets |
||||
| intestinal AlkP (normal) : neuraminidase-insensitive thanks to internal Sia residue => constant pI | enterocytes only in 0 or B blood group individuals => also in faeces | after meals, IBDs |
||||
| placental alkaline phosphatase (PLAP) / heat-stable alkaline phosphatase (HSAP) / secreted embryonic alkaline phosphatase (SEAP) (normal) : the only form not inhibited by EDTA and 100% stable at 56°C for 10' | placenta |
since formation of placenta (pregnancy wk 14-16) to wk 1 after delivery;
preeclampsia |
||||
| fast hepatic or biliary AlkP (pathological) | hepatocytes | as for slow isozymes, plus increased synthesis in HCC |
||||
| Regan carcinoplacental AlkP (pathological) | various carcinomas (pleura, lungs) | |||||
| renal AlkP (pathological) | proximal renal tubule (also in urine) | renal transplant |
||||
| g-glutamyl transferase (gGT) (heterodimer) | 6-28 IU/L at 25°C
9-50 IU/L at 37°C |
1
2 3 4 5 (pathological) Molecular forms are not determinated usually |
spectrophotometry
N-g-glutamyl-p-nitroanilide N-g-glutamyl-naphthylamide |
kidney, pancreas, liver, intestine, lungs, spleen, thyroid, myocardium, many other tissues other than skeletal muscles | liver diseases (hepatitis other (pancreatitis, diabetes mellitus |
asymptomatic condition |
| 5'-nucleotidase | 0-1.6 IU/L at 37°C | AMP + H2O + Mg2+ + Mn2+ =pH 7.5=> Ado + Pi + NH4+MoO4 => violet compound red with spectrophotometry at 630-640 nm; repeat assay with inhibitors (Ni2+, Zn2+) => difference is activity of 5'-nucleotidase only | liver, brain, muscle, kidney, lung, bone, thyroid, endothelium | liver diseases (cholestasis, occupation syndromes, hepatitis |
||
| aspartate transaminase (AST) / serum glutamate-oxalate transaminase (SGOT) : cytosolic and mitochondrial (80%) | 17-22 IU/L at 25°C
25-40 IU/L at 37°C |
Asp + aKG + PPi (not all molecules had it added) =AST=> Glu + OAA =+NADH=MDH=> malate + NAD+ | myocardium, brain, liver, fatty tissue, gastric mucosa, skeletal muscle, kidney, and less pancreas, spleen, testes, RBCs | AMI hepatitis pulmonary and renal infarction myopathies |
||
| alanine transminase (ALT) / serum glutamate-pyruvate transaminase (SGPT) | 15-18 IU/L at 25°C | Ala + aKG + PPi (not all molecules
had it added) =ALT=> Glu + Pyr =+NADH=LDH=> lactate + NAD+
|
liver and less in kidney, myocardium, skeletal muscles, pancreas, spleen |
|
||
| lactate dehydrogenase (LDH) separated
with electrophoresis, nonsandwich IRMA precipitation, tetrazolium salts,
or densitometry; it is heat-unstable and inhibited by guanidine thiocyanate
|
< 120-240 IU/L at 25°C
< 450 IU/L at 37°C |
LDH1 / aKBDH = H4 (at 25°C it also catalyzes aKBut => a-hydroxybutyrate) | myocardium, kidney, RBC (18-33%) | AMI |
11 different mutationsref1, ref2, ref3, ref4, ref5, ref6, ref7, ref8, ref9 (M. Kamada, K. Fujita, I. Sakurabayashi et al., A family with a case of deficiency of lactate dehydrogenase H-subunit. Seibutsu Butsuri Kagaku 36 (1992), pp. 161–164) : 3 base deletion (AAT) at codon 220 of exon 5, which caused a deletion of one asparagineref | |
| LDH2 / H3M1 | myocardium, kidney, RBC, WBC (28-40%) | AMI |
||||
| LDH3 / H2M2 | liver, muscles, WBC (18-30%) | pulmonary infarction, tumors | ||||
| LDH4 / H1M3 | liver, muscles, WBC (6-16%) | hepatopathies, tumors | ||||
| LDH5 / M4 | skeletal muscles, liver (2-13%) | traumas, DMD > 11-24%, hepatopathies, tumors | ||||
| LDH6 / LDHx | testes, hypoxic tissues | renal ischemia and pyelonephritis (not in cystitis), germ
cell tumors |
||||
| creatine phosphokinase (CPK / CK)
: cytosolic and mitochondrial
macro-CPK :
|
at 25°C :
at 37°C : |
CPK1 = BB (oncofetal) | Oxidation of thiols, which reduces activity by 50% in 4-6 hrs at RT can be prevented by glutathione. Spectrophotometric assay with adenylate kinase inhibitors (Mg2+, AMP, diadenosine monophosphate, N-acetyl-cystein). Isozymes can be dosed with sandwich ELISA | brain, smooth muscle (< 1%) | cerebral ischemia, encephalitis, various neoplasms, epilepsy, psychosis | |
CPK2 :
|
myocardium (< 3%) | AMI |
||||
CPK3 :
|
myocardium and skeletal muscles (97%) | physical exercise, intramuscular injections, neuroleptic
malignant syndrome |
||||
| aldolase | 0.5-3.1 IU/L at 25°C | A
B C |
Fru-1,6-bisP => GA3P + DHAP =+NADH=> NAD + glyceraol-3-phosphate | skeletal muscle, myocardium, liver and brain | AMI |
|
| a-amylase (ALS) / diastase | 120-360 IU/L at 37°C | pancreatic amylase
|
Somogyi saccharometric method : maltopentose =>
maltotriose + maltose => 5 Glc =hexokinase => 5 Glc-6-P + 5 NADP+
=> 5 6-phosphogluconolactone + 5 NADPH (l =
340 nm)
chromogenic method : PNP-maltohexose => 2-PNP-maltotriose + H2O =a-glucosidase, basic pH=> Glc + PNP (l = 405 nm) starch => glucose or +I2 => amylose(I)n blue (l = 560-600 nm) |
pancreas >> lungs, testes, ovaries | pancreatic disease :
|
chronic pancreatitis |
salivary amylase or ptyaline
(inhibited by lecithine)
|
salivary glands | parotitis |
||||
| lipases (LPS) | 190 IU/L at 25°C
200 IU/L (0.05-1 conventional units) at 37°C |
pancreatic lipase (acts on sn-1 rather than on sn-2) | activated by Ca2+
|
pancreas and pancreatic ducts | acute pancreatitis, pancreatic carcinoma, tumor or calculus of Vater's ampulla | |
| lipoprotein lipase (activated by heparin) | ||||||
| cholinesterase | true cholinesterase / acetylcholinesterase (AChE) | hydrolysis of thioesters (inhibted by [ACh] > 10-2
M)
acetylthioCh => acetate + ... butirrylthioCh => butyrrate + ... ...thiocholine =+ 5,5'-dithiobis-(2-nitrobenzoate) (DTNB, Ellman reagent)=> 5-thio-2-nitrobenzoate (inhibited by citrate, fluoridde, morphine, quinine, alkaloids, organophosphates; spectrophotometry, l = 405-470 nm) |
RBCs, lungs, spleen, gray matter of brain (cholinergic synapses) | multiple sclerosis, psychoses, schizophrenia (normal in
viral hepatitis, chronic hepatitis, obstructive jaundice, AMI |
paroxysmal nocturnal hemoglobinuria, autoimmune and newborn hemolytic anemia | |
| 3,000-9,000 IU/L at 25°C | serum cholinesterase, benzoylcholinesterase, butrrylcholinesterase or pseudocholinesterase | liver, pancreas, myocardium, white matter, serum | organophosphate poisoning, liver cirrhosis, acute necrotizing hepatitis, HCC, carriers of atypical allozyme have decreased catabolysis of suxamethonium (succinyldicholine) => anaesthetic apnea (lower Kcat and less inhibited by dibucain) | |||
| acid phosphatase (AcP / ACP) | < 11 IU/L at 25°C | very sensitive to L-tartrate (isoforms 2a, 2b and 4) | keep at 4°C with acetate 3 mM (pH = 2) (otherwise decreased activity at 23°C : -30% in 3 hrs, -100% in 3 days). To produce color, the reaction of the ancillary enzyme should be practiced after rising pH with alkaline solution (which also stops reaction) : only then PNP is convertred to quinoid. P-ACP is also dosed with ELISA (as for AlkP) or with subtraction dosing respect to L-tartrate inhibition | granulocytes, pancreas, prostate (but as it flows into seminal fluid, concentration in males and females are roughly the same | metastatic prostatic carcinoma (100-fold increase) (prostatic or osteoclastic
isozyme if bone metastases occur: ACPtotal and P-ACP are poorly
sensitivity in initial stages, when PSA dosage is preferred), hemocytolysis,
sphingolipidoses, Paget's
disease |
|
| moderately sensitive to L-tartrate (isoform 3) | lysosomes (liver, spleen, muscles, stomach, platelets, WBCs) | |||||
| L-tartrate resistant acid phosphatase (5a and 5b isoforms) | hairy cells, osteoclasts, RBCs | |||||
| lactate | spectrophotometry | 2-3 hrs of muscular immobility | ||||
| pyruvate | spectrophotometry | |||||
| amino acids | HPLC |
|
|
|
|
|
|
|
|
deficiency |
| factor I | fibrinogen ABg: a high-molecular-weight plasma protein which is converted to fibrin through the action of thrombin | hepatocytes | - | 340 | 90 | 175-433 mg/dL = 4.0-10.0 mmol/L | afibrinogenemia |
| factor II | prothrombin : a plasma protein that is converted to the active form thrombin (factor IIa) by cleavage by activated factor X (Xa) in the common pathway of blood coagulation; thrombin then cleaves fibrinogen to its active form fibrin | hepatocytes | + | 70 | 60 | 100 (activity : 60-140%) | hypoprothrombinemia |
| factor III | tissue thromboplastin / tissue factor (TF) / CD142 : a lipoprotein expressed on subendothelial fibroblasts and functioning in the extrinsic pathway of blood coagulation, activating factor X | tissues | - | 46 | - | - | |
| factor IV | calcium |
- | - | - | - | - | |
| factor V | proaccelerin / accelerator globulin (AcG) / labile factor : a heat- and storage-labile material, present in plasma but not in serum, functioning in both the intrinsic and extrinsic pathways of blood coagulation, catalyzing the cleavage of prothrombin to the active thrombin. When adsorbed to platelets it is called platelet factor 1 (PF1) | hepatocytes, megakaryocytes | - | 330 | 18-25 | 10 (activity = 60-140%) | parahemophilia |
| a factor (accelerin) previously thought to be an activated form of factor V. It is no longer considered in the scheme of hemostasis, and hence it is currently assigned neither a name nor a function | - | - | - | - | - | ||
| factor VII | proconvertin / serum prothrombin conversion accelerator (SPCA) / stable factor : a heat- and storage-stable factor participating in the extrinsic pathway of blood coagulation. It is activated by contact with calcium and in concert with factor III (tissue thromboplastin) activates factor X. The activated form is called also convertin | hepatocytes | + | 48 | 5-6 | 0.13-1.00 (activity = 70-130%) | hereditary
(autosomal recessive) |
| factor VIII |
![]() |
hepatocytes, RES | - | 300 | 10-14 | 0.05-0.15 (activity = 50-200%) | hemophilia A
(classical hemophilia) |
| factor IX | plasma thromboplastin component (PTC) / autoprothrombin II / Christmas factor / antihemophilic factor B : a relatively storage-stable substance involved in the intrinsic pathway of blood coagulation; upon activation, it activates factor X | hepatocytes | + | 57 | 20-25 | 5 (activity = 60-140%) | hemophilia B |
| factor X | autoprothrombin C / Stuart-Prower factor : a storage-stable factor that participates in both the intrinsic and extrinsic pathways of blood coagulation, uniting them to begin the common pathway of coagulation. Once activated, (factor Xa) it forms a complex with calcium, phospholipid, and factor V; the complex (prothrombinase) can cleave and activate prothrombin to thrombin. The activated form is called also thrombokinase | hepatocytes | + | 59 | 40-60 | 12 (activity = 70-130%) | systemic coagulation disorder |
| factor XI | plasma thromboplastin antecedent (PTA) / antihemophilic factor C : a stable factor involved in the intrinsic pathway of blood coagulation; once activated (factor XIa), it activates factor IX | hepatocytes | - | 160 | 50-65 | 3-6 (activity = 60-140%) | hemophilia
C |
| factor XII | Hageman, glass, contact, or activation factor : a stable factor
activated to factor XIIa by contact with glass or other foreign surfaces,
which initiates the intrinsic process of blood coagulation by activating
factor
XI and participates in activation of the kinin and fibrinolytic pathways
|
hepatocytes | - | 80 | 55-60 | 30 (activity = 60-140%) | thrombotic
disorders |
| factor XIII | fibrin-stabilizing factor (FSF) / fibrinase / protransglutaminase / Laki-Lorand factor (A1 and A2 polypeptides) : a factor that polymerizes fibrin monomers so that they become stable and insoluble in urea, thus enabling fibrin to form a firm blood clot. The activated form is also called transglutaminase. | megakaryocytes, hepatocytes | - | 320 | 90-150 | 10-20 | hemorrhagic
diathesis |
| Fletcher factor / prekallikrein | a plasma protein that is the proenzyme of plasma kallikreins |
hepatocytes | - | 86 | 58 | 50 | |
| hepatocytes | - | 120 | 168 | 70-90 |
|
|
|
|
|
||
| anticoagulants | a2-macroglobulin | 725 | 210 | kallikrein, FXIIa, FXIa, FIXa, FXa, thrombin, plasmin, elastase, FXIa | none |
| a1-antitrypsin | 50 | 300 | elastase, plasmin, FXIa | pulmonary emphysema, liver cirrhosis | |
| C1-INH |
105 | 24 | kallikrein, FXa, thrombin | angioneurotic edema | |
| glucosaminoglycans (GAGs) |
|||||
| antithrombin III / heparin cofactor I | 58 | 29 | kallikrein, FXIIa, FXIa, FIXa, FXa, thrombin | juvenile venous thromboembolism | |
| heparin cofactor II | 66 | 9 | thrombin | juvenile venous thromboembolism | |
| protein C | 62 | 0.4 | FVa, FVIIIa | juvenile venous thromboembolism | |
| complement S-protein / vitronectin | 69 | 1 (free; higher in males) | activated protein C cofactor | juvenile venous thromboembolism | |
| CD141 / thrombomodulin | |||||
| PGI2 / prostacyclin |
|||||
| tPA | |||||
| LACI / thrombin-activatable fibrinolysis inhibitor (TFPI) | 33 | <= 0.01 | TF/FVIIa, FXa | ||
| antifibrinolytics | a2-antiplasmin | 67 | 7 | plasmin | hyperfibrinolysis |
| plasminogen activator inhibitor type 1 (PAI-1) / SERPINE1 | 105 | 24 | t-PA | hyperfibrinolysis | |
| tissue factor (TF) | |||||
| vWF |

|
|
|
|
|